FDA designates Scynexis antibiotic SCY-078 'qualified infectious disease' product

The FDA has designated Scynexis' investigational antibiotic SCY-078, previously known as MK-3118, a qualified infectious disease product (QIDP) – a status that could garner the experimental medicine an additional five years of market exclusivity if approved for oral use for the indications of invasive Candidiasis, including Candidemia and invasive Aspergillosis.